Atopic Dermatitis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030  

Atopic Dermatitis Pipeline Drugs Assessment Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030  

Atopic dermatitis is a chronic, pruritic inflammatory skin disease with unknown origin. It generally occurs in children but affects a substantial number of adults.Symptoms include dry skin, itching, red to brownish-grey patches especially on hands, neck, upper feet, legs, inside the bend of elbows, knees and other parts of the body. Atopic dermatitis generally examined through the physical examination. No cure has been found for atopic dermatitis, but the treatment is given for relieving the symptoms. Treatment may include topical applications to relieve the itching, oral drugs to control the inflammation and drugs for infection control.Food and Drug Administration (FDA) has recently approved a new, injectable monoclonal antibody, dupilumab for the treatment of severe atopic dermatitis.

 Key Developments:

Currently, there is no availability of effective treatments to treat atopic dermatitis. Most of the drugs are used to relieve the symptoms. Two Janus kinase inhibitors approved for rheumatoid arthritis and myelodysplasia. One of these drugs isstudied for atopic dermatitis but drug is not actively developed now. Many Janus kinase inhibitors are in clinical trial stages for treatment of atopic dermatitis.

  • In March 2017, LEO Pharma announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD).
  • In January 2017, AbbVie announced that the U.S. FDA granted Breakthrough Therapy Designation for the investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

 

Atopic Dermatitis Disease Pipeline Drugs Assessment Dynamics

Atopic Dermatitis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Atopic Dermatitis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Atopic Dermatitis disease pipeline drugs development. This report studies the dynamics of the Atopic Dermatitis Disease Pipeline Drugs i.e. drivers, challenges, and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Atopic Dermatitis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development

Atopic Dermatitis Pipeline Drugs Assessment Segmentation Analysis

Report Benchmarks

Details

By Route of Administration

  • Oral
  • Topical
  • Parenteral

By Trial Phase

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

 

  1. Executive Summary
  2. Global Atopic Dermatitis Pipeline Drugs Assessment Market Introduction
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Taxonomy
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Definitions
      • Route of Administration
      • Trail Phase

3. Global Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics

    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Competition Landscape
    • Epidemiolog
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2018 2024
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%)
      • Market OpportunityAnalysis
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Topical
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market Forecast, By Trail Phase,2019 - 2023 and Forecast, 2018 2024
    • Preclinical Trials
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Atopic Dermatitis Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Region, 2018 2024
  2. North America Atopic Dermatitis Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 2024
    • North America Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics Trends
  3. Europe Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 2024
    • Europe Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics Trends
  4. Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 2024
    • Asia-Pacific Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics Trends
  5. Latin America Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 2024
    • Latin America Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics Trends
  6. Middle East and Africa Atopic Dermatitis Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Oral
      • Topical
      • Parenteral
    • Trail Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Atopic Dermatitis Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Route of Administration, By Trail Phase, and Country, 2018 2024
    • MEA Atopic Dermatitis Pipeline Drugs Assessment Market Dynamics Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AbbVie Inc. (U.S.)
      • Sterna Biologicals GmbH & Co. KG (Germany)
      • Santalis Pharmaceuticals, Inc. (U.S.)
      • MedImmune LLC (U.S.)
      • Eli Lilly and Company (U.S.)
      • Regeneron Pharmaceutical (U.S.)
      • Sienna Biopharmaceuticals (U.S.)
      • Others
  8. Research Methodology
  9. Key Assumptions and Acronyms

 

Key Market Players

  • AbbVie Inc. (U.S.)
  • Sterna Biologicals GmbH & Co. KG (Germany)
  • Santalis Pharmaceuticals, Inc. (U.S.)
  • MedImmune LLC (U.S.)
  • Eli Lilly and Company (U.S.)
  • Regeneron Pharmaceutical (U.S.)
  • Sienna Biopharmaceuticals (U.S.)

Related Industry Reports